abstract |
The present invention generally relates to the preparation and characterization of neutralizing anti-IFN- [alpha] monoclonal antibodies with broad reactivity for various IFN- [alpha] subtypes. The invention also relates to the use of an anti-IFN-a antibody for the diagnosis and treatment of disorders associated with increased expression of IFN-a, in particular autoimmune disorders such as insulin dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE) It is related to use. |